Despite the presence of strong neutralizing antibodies in a number of SBBC members, 57 disease progression was not prevented and each cohort member studied displayed a 58 unique outcome of infection with nef-attenuated HIV-1.
Introduction
was low by comparison (unpublished). Subjects D36 and C98 were placed on 94 antiretroviral therapy in 1999 (9) . Subjects C49, C64 and C135 are long-term non-95 progressors (LTNP) as they have remained asymptomatic with undetectable plasma viral 96 loads and stable CD4 + T-cell counts (3, 9, 33) . (ARCBS, Melbourne, Victoria, Australia), taken from healthy, HIV-1 seronegative 145 individuals, as described previously (53) . PBMC were maintained in RF10 medium 146 (RPMI-1640 medium supplemented with 10% (vol/vol) fetal bovine serum, 25µg/ml L-147 glutamine, 100U/ml penicillin, and 100µg/ml streptomycin), and were activated using 148 10µg/ml phytohemagglutinin (PHA) 72hr prior to use. Donor PBMC were selected for 149 their ability to support the replication of primary and nef-attenuated isolates prior to use. 150
151

Viruses 152
The HIV-1 isolates HIV-1 NL43 infection and culture of 3-day PHA-activated PBMC in IL-2 media (RF10 containing  163 12mM HEPES, 10U/ml IL-2, 0.2% polybrene, and 0.1% hydrocortisone). 164
165
Virus was isolated from SBBC PBMC using standard PBMC co-culture techniques (41) . 166
Subject PBMC were isolated from fresh whole blood as described (53) , and were co-167 cultured with selected activated donor PBMC for up to 28 days. Culture supernatant was 168 tested for cell-free reverse transcriptase (RT) activity (49) and/or extracellular p24 169 antigen by EIA (Biomérieux, Baulkham Hills, NSW, Australia). For some isolations 170 prior to 1996, subject PBMC were irradiated with ultraviolet light prior to co-culture to 171 promote virus production from latently infected cells (52) . 172
173
Virus was isolated from plasma collected from subject Nef1 by centrifugation over a 20% 174 w/v sucrose cushion at 45,000 × g using a Heraeus Biofuge Stratos centrifuge. Pelleted 175 virus was resuspended in IL-2 medium containing 5 × 10 6 selected activated donor 176 PBMC, and cultured for 14 days. Culture supernatant was tested for cell-free RT activity. 177
178
Coreceptor usage assay 179
Virus coreceptor usage was analyzed as described previously (19) (20) (21) . Briefly, Cf2-Luc 180 cells were transfected with CD4 alone, or co-transfected with CCR2b, CCR3, CCR5, 181
Western blot 186
HIV-1 viral lysate-based Western blots were performed using total IgG or IgG 3 187 secondary antibodies as described previously (56) . 188
189
Neutralization assay 190
Plasma (25µl, to give final twofold dilutions from 1:100 to 1:3200 except where 191 otherwise stated) was added to 50µl of 10,000 TCID 50 /ml HIV-1, or 50µl of neat culture 192 supernatant if less than 10,000 TCID 50 /ml, in quadruplicate wells of a 96-well tissue 193 culture plate. This mixture was incubated for 1 hr at 37°C and 5% CO 2 
Results
203
Virus isolation 204
To facilitate autologous antibody testing for SBBC members, virus isolation was 205 attempted for the eight members studied via co-culture of subject PBMC with selected 206 seronegative donor PBMC. Success of isolation correlated with coincident plasma viral 207 load for the majority of samples tested ( revealed no association with viral load. Plasma from subjects S2 and S12 had strong 258 reactivity to numerous HIV-1 proteins, whereas plasma from S1, S4 and S13 showed 259 weak reactivity to single proteins (data not shown). 260 261
Neutralization of nef-attenuated HIV-1 is associated with viral phenotype and viral 262 load 263
Plasma from selected members of the nef-attenuated and control cohorts were tested for 264 neutralization of two SBBC isolates, HIV-1 D36III and HIV-1 C18(2) , using PBMC (Table 3) . 265
Results shown are from representative experiments using the same donor PBMC, 266 allowing reproducible cross-comparisons (13) . Experiments in our laboratory showed 267 that measurement of neutralization using the RT assay was reproducible and comparable 268 to results gained using the p24 antigen assay (data not shown). For the nef-attenuated 269 group, virus neutralization was associated with viral load, replication of isolated virus, 270 and the strength of antiviral IgG responses; C54 was the exception. The most potent 271 neutralization was observed for plasma derived from subjects D36, C18, and Nef1. (Table 4 ). Potent neutralization was observed for plasma derived from Nef1 and 284 C18, and to a lesser extent for D36, C54, and C98. Little or no neutralization was 285 observed for plasma derived from C49, C64, and C135. Plasma derived from subject 286 C18 was able to strongly neutralize HIV-1 ROK39 (clade A), HIV-1 SE364 (clade C), HIV-287 1 BCB93 (clade D), and HIV-1 92TH024 (CRF01_AE), while plasma from C98 was only able 288 to weakly neutralize HIV-1 ROK39 and HIV-1 SE364 . Neutralization of clade B isolates by 289 plasma derived from members of the control group varied, with plasma from S13, and to 290 a lesser extent S1, S2, and S4 strongly neutralizing with no neutralization observed for 291 plasma from S12. HIV-1 MBC925 , a brain-derived CCR5-using strain isolated from a 292 patient with AIDS, was the most difficult clade B isolate to neutralize, with only three 293 plasma samples (C18(2), Nef1, and S13) showing moderate neutralization of this isolate. 294 This is consistent with previous findings (37) . Together, these isolates represent a diverse 295 group of viruses to be neutralized, some which have been used in other neutralization 296 studies, including both R5 and X4 phenotypes (2, 28, 37, 40) . 297 298
Changes in neutralization over time 299
Sequential plasma samples derived from the five SBBC members from whom virus had 300 been isolated (D36, C18, C54, C64, and C98) were tested for their ability to neutralize 301 virus isolated from the same individual at different timepoints (Table 5 ). For subject 302 D36, virus isolated at 14.5 years post-infection (D36III), prior to increasing viral load and 303 decreasing CD4 + T-cell count, showed increased neutralization sensitivity compared with 304 virus isolated at later timepoints. D36 plasma from early timepoints was able to 305 neutralize autologous virus, before neutralization decreased accompanying signs of 306 disease progression.
Interestingly, neutralization titres increased following the 307 commencement of antiretroviral therapy. 308
309
Only two samples were available for subject C18 after monitoring began and prior to the 310 death of the subject in 1995. Both C18(2) and C18(4) plasma were strongly able to 311 neutralize autologous virus, although neutralization titres declined marginally for C18 (4) group, who showed a range of detectable viral loads (3700 to 79,000 RNA copies/ml for 360 S13 and S4, respectively). Members of the control group showed a much narrower range 361 of IgG responses compared with the nef-attenuated cohort. Interestingly, plasma derived 362 from Nef1, C18, and C54 showed p24 antigen-specific IgG 3 isotype responses by 363
Western blot, as well as S4 and S13 by EIA, previously identified in our laboratory to be 364 a marker of early HIV-1 infection when tested with seroconversion panels (56) . For the members studied in the nef-attenuated cohort, the strongest antibody responses 416 were observed for individuals with low but detectable viral load set points, less than 417 10,000 copies/ml. This is consistent with the recent observation of an undetectable viral 418 load and weak, delayed antibody responses in an unrelated individual infected with nef-419 attenuated HIV-1 (30) . Although Nef1 appears to be an exception, viral load data for this 420 individual was available for only the single timepoint tested. (4) 540 plasma. NT -not tested. 541 542 samples from SBBC members from whom HIV-1 had been isolated (D36, C18, C54, 545 C64, and C98) were tested for neutralization of sequential virus isolates from the same 546
individual. Plasma samples were tested at twofold dilutions from 1:100 to 1:3200, except 547 for C64 plasma (1:25 to 1:800). Replication was measured by cell-free RT activity 548 except for HIV-1 C54IV and HIV-1 C54XV , which were analyzed for supernatant p24 antigen 549 production. ID 50 Tables  554   Table 1a (overleaf) 555 Table 2 Virus Coreceptor usage Seronegative N/A <25 <25 C64 IV <100 <100 236 <100 <100 <100 <100 <100
A C C E P T E D
CCR2b CCR3 CCR5 CCR8 CXCR4 CX3CR1 Gpr1 Gpr15 Strl33 Apj NL4-3 - - - - +++ - - - - + ADA - ++ +++ + - +/- - + + + 89.6 + ++ +++ - +++ - +/- - - + D36 II +/- - ++ - +++ - - - - - D36 VIII +/- - +++ - +++ - - - - - D36 IX +/- - +++ - +++ - - - - - D36 XI +/- - +++ - +++ - - - - - C18 (2) - + +++ - - - - + - - C18 (4) - + +++ - - - - + - - C54 III +/- + ++ - - - - - - - C54 VIII +/- + ++ - - - - - - - C54 XIV +/- + +++ - - - - - - - C64 IV - - ++ - - - - - - - C98 I - + ++ - - - - - - - C98 VI - + +++ - - - - - - - C98 XIV - + +++ - - - - - - -
C98 IV 184 <100 1929 <100 <100 <100 <100 <100 
S1
NT NT >3200 <100 2440 208 <100 <100
S2
NT NT 1454 <100 1153 302 <100 <100
S4
NT NT >3200 <100 2052 <100 <100 <100 S12 NT NT <100 <100 <100 <100 <100 <100 S13 NT NT >3200 449 >3200 1196 1302 532
Seroneg.
NT NT <25 <25 <25 <25 <25 <25 C18 (2) >3200 <100 >3200 263 2128 325 >3200 <100
C98 IV 551 <100 305 <100 <100 <100 <100 <100 
A C C E P T E D
